Mannkind, Game-Chancer in Sachen Diabetik? (Seite 539)

[Wuothan]

Sehen wir heute noch die 8$ vorm Komma ... ??? Lustig seeking alpha schreibt sich die Finger wund und die Ami´s folgen denen wie Schafe. --> es nervt !

[sunny3999]

15 Mio gehandelt bei 9,30 $ ich kann es nicht fassen....

[Magnetfeldfredy]

Die Drecksshorts sollen verrecken, medizinische Gamechanger versuchen zu verhindern , schlecht zu reden..................

[Jagubert]

Zitat von Niller84: Der Kurs bringt mich gerade zum Verzweifeln, würde heute gerne mal clean sheet machen, aber 9,4 klingt einfach lächerlich mit der News!:-(

Dito.
Jede gute Nachricht bewirkt genau das Gegenteil dessen was zu erwarten gewesen wäre.
Schade das nicht einmal die $10 stabil halten.

[ABC-Schuetze]

Antwort auf Beitrag Nr.: 47.486.038 von Niller84 am 11.08.14 15:44:55

Heutte Moregen wären doch 11 möglich gewesen.

[Niller84]

Der Kurs bringt mich gerade zum Verzweifeln, würde heute gerne mal clean sheet machen, aber 9,4 klingt einfach lächerlich mit der News!:-(

[ABC-Schuetze]

http://www.morgenpost.de/wirtschaft/article131106145/Diabeti…

[ABC-Schuetze]

Q2:

MannKind Corporation Reports 2014 Second Quarter Financial Results

VALENCIA, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the second quarter ended June 30, 2014.

For the second quarter of 2014, total operating expenses were $69.8 million, compared to $41.6 million for the second quarter of 2013, an increase of $28.2 million, largely due to an increase in non-cash stock compensation expense of $30.5 million. In the second quarter of 2014, the settlement terms for certain performance-based awards were modified requiring reclassification of these performance grants from equity awards to liability awards and resulting in incremental stock-based compensation expense. Research and development (R&D) expenses increased by $10.2 million to $37.3 million for the second quarter of 2014 compared to $27.1 million for the same quarter in 2013. This 38% increase in R&D expense was primarily due to increased non-cash stock compensation expense of $13.1 million and increased commercial readiness costs of $1.4 million offset by a $4.2 million decrease in clinical trial related expenses. General and administrative (G&A) expenses increased by $18.0 million to $32.5 million for the second quarter of 2014 compared to $14.5 million in the second quarter of 2013. This 124% increase in G&A expense was primarily due to increased non-cash stock compensation expense of $17.3 million.

For the first six months of 2014, operating expenses totaled $111.3 million, compared to $78.0 million in the first half of 2013. The increase of $33.3 million was largely due to an increase in non-cash stock compensation of $36.2 million. Total R&D expenses for the six months ended June 30, 2014 increased by $10.1 million compared to the same period in 2013, primarily due to a $15.5 million increase in non-cash stock compensation expense along with a $2.7 million increase in spending on commercial readiness. This 19% increase was offset by an $8.3 million decrease in clinical expenses upon the completion of the Affinity studies in the second quarter of 2013. G&A expenses increased by $23.2 million, or 94%, to $47.8 million for the first half of 2014 as compared to $24.6 million in the same period in 2013, primarily due to increased non-cash stock compensation expense of $20.7 million and an increase in consulting and legal fees of $1.5 million related to financing transactions and associated filings.

The net loss applicable to common stockholders for the second quarter of 2014 was $73.4 million, or $0.19 per share based on 380.8 million weighted average shares outstanding, compared to a net loss applicable to common stockholders for the second quarter of 2013 of $46.1 million, or $0.16 per share based on 284.0 million weighted average shares outstanding. The number of common shares outstanding at June 30, 2014 was 394,036,984.

Cash and cash equivalents were $41.2 million at June 30, 2014, compared to $35.8 million in the first quarter of 2014. In the second quarter of 2014, $16.3 million in proceeds from warrant and stock option exercises were received in addition to $20.0 million from Tranche B notes purchased by Deerfield. Subsequently, on July 18, 2014, $40.0 million in Tranche 4 notes were purchased by Deerfield under the provisions of the facility agreement upon FDA approval of AFREZZA. Currently, up to $70.0 million of additional sales of Tranche B notes to Deerfield remain available and there is also $30.1 million of available borrowings under the amended loan arrangement with The Mann Group.

Conference Call

MannKind management will host a conference call to discuss these results today at 5:00 p.m. Eastern Time. To participate in the call please dial [phone] or [phone] and use the participant passcode: 36435006. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at www.mannkindcorp.com.

[sunny3999]

Zitat von Niller84: Hey Sunny, guter und interessanter Link zur Pressekomferenz!:-) Denkst du wirklich das Mannkind bis auf 10Mia steigen wird und in welchen Zeitrahmen?

Kann man wirklich nicht sagen, der Partnerdeal ist großartig viel positives, alle Risiken sind mit einem Mal weg.

Die Frage ist welchen Stellenwert wird die Sales Truppe von Sanofi - Afrezza geben...wenn Easy-to-use dahinter vermerkt wird...könnten die Ergebnisse für die Meilensteine schnell erreicht werden.

Die Umsätze die Mannkind generiert werden wohl Aufschluss über Erfolg oder Misserfolg geben....250 Mio Verkauf an Afrezza sollte dies schnell erreicht sein...wer die erste Meßmarke wann in welcher Zeit dies erreicht wird.

Ich denke 10 Mrd MK ist in keinem Fall übertrieben zumal noch weitere Produkte in der Pipeline stecken und sich entfalten können.

Ich bin dennoch etwas enttäuscht über den vorbörslichen Kursverlauf, hoffe es geht wieder nach oben nach der Eröffnung....

[ABC-Schuetze]

Post by chauffe00 on 4 minutes ago

virtually all the analysts on the conference call have said CONGRATS ON THE GREAT DEAL!!!


Read more: http://www.mnkd.proboards.com/thread/1138/webcast-link-30am-…